. 2022 Mar 23;158(5):513–522. doi: 10.1001/jamadermatol.2022.0364

Table 4. Comparison of Treatment Classes Among Patients Without Associated Inflammatory Disease (Subgroup Analyses) Using Inverse Probability of Treatment Weighting Cox Proportional Hazards Regression Models and Adjustment for Time-Dependent Covariables^a.

Patient cohort	IPTW
	IL-17 vs TNF inhibitors		IL-12/23 vs TNF inhibitors			IL-17 vs IL-12/23 inhibitors
	Weighted HR (95% CI)	P value	Weighted HR (95% CI)	P value	Weighted HR (95% CI)		P value
Psoriasis (n = 12 972)	0.73 (0.68-0.78)	<.001	0.71 (0.67-0.76)	<.001	1.02 (0.94-1.11)		.63
Psoriatic arthritis (n = 3193)	0.73 (0.58-0.92)	<.001	1.19 (0.98-1.44)	.07	0.61 (0.46-0.82)		<.001

Abbreviations: HR, hazard ratio; IL-12/23, interleukin 12 and interleukin 23; IL-17, interleukin 17; IPTW, inverse probability of treatment weighting; TNF, tumor necrosis factor.

^{^a}

Includes conventional synthetic disease-modifying antirheumatic drugs and prednisone.

Table 4. Comparison of Treatment Classes Among Patients Without Associated Inflammatory Disease (Subgroup Analyses) Using Inverse Probability of Treatment Weighting Cox Proportional Hazards Regression Models and Adjustment for Time-Dependent Covariablesa.

Table 4. Comparison of Treatment Classes Among Patients Without Associated Inflammatory Disease (Subgroup Analyses) Using Inverse Probability of Treatment Weighting Cox Proportional Hazards Regression Models and Adjustment for Time-Dependent Covariables^a.